Dalton Transactions · 2014 · 36 citations · 31 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyCellular PharmacologyMolecular PharmacologyIon Channel PharmacologyIon Channel SignalingPharmacodynamics Of Anticancer AgentsPotassium Channel BiophysicsAnticancer ActivityDrug Binding To Ion ChannelsIon Channel Structure-function RelationshipsPotassium Channel PharmacologyPotassium Channel Physiology
We report here that the established anticancer ruthenium(iii) complex NAMI-A induces potent and selective cytotoxic effects in a few leukaemia cell lines. These results sound very surprising after 20 years of intense studies on NAMI-A, commonly considered as a "non-cytotoxic" antimetastatic agent. In addition, evidence is given for selective inhibition of KCa 3.1 channels. The implications of these findings are discussed.
31
Jeany M. Rademaker-Lakhai, H.J.G.D. van den Bongard, Dick Pluim et al. · Clinical Cancer Research · 2004 · 823 citations · Full text
Medicine, Oncology, Pharmacology +12
Ruthenium Anticancer Compounds: Challenges and Expectations
I. Bratsos, S. Jedner, Teresa Gianferrara et al. · CHIMIA International Journal for Chemistry · 2007 · 225 citations · Full text